A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Inclusion Criteria: * Active Multiple Myeloma Stage II or III Durie Salmon * Measurable levels of myeloma paraprotein in serum (≥1.0g/dL) or urine (≥ 0.2g excreted in a 24-hour collection sample) * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 * Women of child bearing potential must agree to abstain for heterosexual intercourse or use 2 methods of contraception, one effective (for example hormonal or tubal ligation) and one barrier (for example latex condom, diaphragm) * Males must agree to use barrier contraception (latex condoms) when engaging in reproductive activity Exclusion Criteria: * Pregnant or lactating females * Peripheral neuropathy ≥ to grade 2 of the NCI CTC. * Prior history of malignancy unless subject has been free of disease for ≥ 3 years * Lab abnormality: Absolute neutrophil count (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L) * Lab abnormality: Platelet count \<50,000/mm\^3 (50.0 x 10\^9/L) * Lab abnormality: Serum creatinine \>3.0 mg/dL (265 µmol/L) * Lab abnormality: Serum glutamic oxaloacetic transaminase (SGOT) /Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine transaminase (ALT) \>3.0 x upper limit of normal (ULN) * Lab abnormality: Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)